REMEDY Act

The REMEDY Act (S 2620) modifies how generic drug manufacturers certify patents when seeking FDA approval. It requires drug companies to select one specific patent upfront as the "covered patent" for the 30-month delay period (which blocks generic competition), and they cannot change this selection later. This targets "evergreening" tactics where brand-name drug companies list multiple patents to extend monopolies. The bill directly affects pharmaceutical companies filing generic applications and the FDA's patent review process.